GlassScriptPhysician profile
Michael A Campenni
NPI 1053313478
$6,419.64
in general payments reported to CMS, 2019-2025
31 companies · $811 in 2025
The $811 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $1,088 · 2021: $1,172 · 2022: $1,046 · 2023: $471 · 2024: $310 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,464.44 | 2019-2025 | |
| Astellas Pharma US INC | $1,205.85 | 2019-2024 | Myrbetriq, Veozah |
| Pfizer INC. | $1,103.96 | 2019-2022 | |
| Abbvie INC. | $452.76 | 2019-2024 | Lupron Depot |
| Teleflex LLC | $361.34 | 2021-2025 | Urolift, Barrigel |
| Sumitomo Pharma America, INC. | $242.27 | 2023-2025 | Gemtesa |
| Medtronic, INC. | $237.54 | 2021-2025 | Interstim, Altaviva |
| Dentsply Ih Ab | $173.36 | 2024-2025 | Lofric |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Novo Nordisk INC | $115.97 | 2021 | |
| Alkermes, INC. | $94.88 | 2021 | |
| Endo Pharmaceuticals INC. | $93.85 | 2019-2021 | |
| Allergan, INC. | $87.76 | 2019-2020 | |
| Medtronic USA, INC. | $81.36 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $79.16 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.07 | 2020-2023 | Zinplava, Recarbrio, Dificid |
| Laborie Medical Technologies Corp. | $53.92 | 2023 | |
| Coloplast Corp | $48.73 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $47.33 | 2019-2021 | |
| Boston Scientific Corporation | $37.71 | 2019-2023 | Spaceoar Vue System - 10ml |
| Takeda Pharmaceuticals U.S.A., INC. | $34.74 | 2022 | |
| Neotract INC. | $31.76 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.59 | 2022 | |
| 180 Medical, INC. | $25.90 | 2019 | |
| Axonics, INC. | $23.04 | 2023 | Bulkamid |
| Ardelyx, INC. | $21.72 | 2023 | Ibsrela |
| Olympus America INC. | $21.33 | 2021 | |
| Antares Pharma, INC. | $18.85 | 2021 | |
| Rochester Medical Corporation | $15.88 | 2019 | |
| Foundation Medicine, INC. | $15.16 | 2020 | |
| Photocure INC | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Campenni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.